tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis
PremiumRatingsSionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis
1M ago
Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
Premium
The Fly
Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
2M ago
Sionna downgraded to Underperform from Sector Perform at RBC Capital
Premium
The Fly
Sionna downgraded to Underperform from Sector Perform at RBC Capital
2M ago
Sionna Therapeutics reports Q3 EPS (46c), consensus (47c)
PremiumThe FlySionna Therapeutics reports Q3 EPS (46c), consensus (47c)
3M ago
Sionna Therapeutics expects cash to fund operations into 2028
Premium
The Fly
Sionna Therapeutics expects cash to fund operations into 2028
3M ago
Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study
Premium
Company Announcements
Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study
3M ago
Sionna Therapeutics initiated with a Buy at JonesResearch
PremiumThe FlySionna Therapeutics initiated with a Buy at JonesResearch
5M ago
Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
Premium
Ratings
Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
5M ago
Short Report: Frontier Group short positioning continues gaining altitude
Premium
The Fly
Short Report: Frontier Group short positioning continues gaining altitude
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100